Janux Therapeutics ( NASDAQ:JANX ) has made waves with promising interim early-stage data for its experimental therapy targeting advanced prostate cancer. Shares of the drug developer skyrocketed, more than doubling in value following the announcement, as investors rallied behind the optimistic trial results. Groundbreaking Trial Data The candidate, JANX007,...
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that,...
Less certain about this one as we technically have not confirmed a pivot. A certain portions of our positions will have a more aggressive approach applied to them. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci...